Patrys shares rise as 10-year data shows PAT-SC1 improves survival
Australian biotech companyPatrys (ASX: PAB) has published 10-year follow up data for its product PAT-SC1 showing that it is well-tolerated in gastric cancer patients and offers a significant survival benefit.
Patrys said it is currently seeking an out licensing partner for PAT-SC1. The company’s shares were trading 6.52% higher at $0.049 on Wednesday on the news.
This article in Oncology Reports is based on a study conducted between 1997 and 2001 that investigated the effect of PAT-SC1 in patients with gastric cancer who had also undergone gastric resection surgery. It has been previously shown that a single 20mg dose of PAT-SC1 administered before surgery induced cell killing in human primary gastric tumours, leading to tumour cell regression in over half of PAT-SC1-treated patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze